ArticleHIV

Laboratoire Rodolphe Mérieux de Phnom Penh

Population pharmacokinetic-pharmacogenetic study of Nevirapine in HIV-infected Cambodian patients

M. CHOU, J. BERTRAND, O. SEGERAL, C. VERSTUYFT, L. BORAND, E. COMETS, C. LE TIEC, L. BECQUEMONT, V. OUK, F. MENTRE, Anne-Marie TABURET

Antimicrob Agents Chemother. 2010 Oct;54(10):4432-9

Abstract

Objective: Tuberculosis is the major opportunistic infection of HIV/AIDS in developing countries. We investigated the prevalence rate of multidrug-resistant (MDR) tuberculosis at an HIV voluntary counseling and testing (VCT) center in Port-au-Prince, Haiti.
Design and methods: A cross-sectional prevalence study of MDR-tuberculosis was conducted at a VCT Center. All patients reporting at least 5 days of cough were screened for tuberculosis, including sputum culture. All Mycobacteria tuberculosis isolates underwent drug susceptibility testing.
Results: Between January 2000 and December 2002, isolates from 330 patients underwent drug susceptibility testing. MDR-tuberculosis was documented in 16 (6%) of 281 patients with primary tuberculosis and 10 (20%) of 49 patients with recurrent tuberculosis. In patients with primary disease, 11 (10%) of 115 HIV-infected patients had MDRtuberculosis compared with five (3%) of 166 HIV-negative patients, (risk ratio 3.2; 95% confidence interval 1.1–8.9; P 1/4 0.0331).
Conclusions: Multidrug resistance was prevalent among patients found to have pulmonary tuberculosis at an HIV testing center in Port-au-Prince. Patients with primary pulmonary tuberculosis who were HIV-co-infected were more likely to have multidrug resistance than HIV-negative patients. Assiduous attention to tuberculosis infection control measures at HIV testing centers in developing countries is critical to prevent nosocomial MDR-tuberculosis transmission. Measures may include appropriate ventilation, outdoor seating, ultra-violet lights, and rapid on-site screening for tuberculosis. Keywords: HIV, multidrug-resistant tuberculosis, Haiti

View article